{
    "xml": "<topic id=\"PHP5662\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/rituximab\" basename=\"rituximab\" title=\"RITUXIMAB\">\n<title>RITUXIMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1300\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/rituximab\">Rituximab</xref>\n</p>\n<data name=\"vtmid\">108809004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_402717286\" title=\"Monoclonal antibodies (anti-lymphocyte)\">Monoclonal antibodies (anti-lymphocyte)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n</data>\n</data>\r\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP49893\" outputclass=\"indicationsAndDose\" rev=\"1.38\" parent=\"/drugs/rituximab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (in combination with methotrexate)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;g, then 1&#8239;g after 2&#8239;weeks, patients should receive premedication before each infusion (consult product literature for details).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of previously untreated stage III&#8211;IV follicular lymphoma (in combination with other chemotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (in combination with other chemotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of diffuse large B-cell non-Hodgkin's lymphoma (in combination with other chemotherapy)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of chemotherapy-resistant or relapsed stage III&#8211;IV follicular non-Hodgkin's lymphoma</p>\n<p outputclass=\"therapeuticIndication\">Previously untreated or relapsed chronic lymphocytic leukaemia</p>\n<p outputclass=\"therapeuticIndication\">Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis (in combination with glucocorticoids)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Patients should receive premedication before each dose (consult product literature for details) (consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49952\" outputclass=\"contraindications\" rev=\"1.25\" parent=\"/drugs/rituximab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)</ph>; <ph outputclass=\"contraindication\">severe infection</ph>; <ph outputclass=\"contraindication\">severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>For full details on contraindications, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49978\" outputclass=\"cautions\" rev=\"1.42\" parent=\"/drugs/rituximab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<title>General cautions:</title>\n<p>\n<ph outputclass=\"caution\">History of cardiovascular disease; in adults exacerbation of angina, arrhythmia, and heart failure have been reported</ph>; <ph outputclass=\"caution\">patients receiving cardiotoxic chemotherapy; in adults exacerbation of angina, arrhythmia, and heart failure have been reported</ph>; <ph outputclass=\"caution\">transient hypotension occurs frequently during infusion (anti-hypertensives may need to be withheld for 12 hours before infusion)</ph>\n</p>\n<sectiondiv outputclass=\"additionalCautions\">\n<p outputclass=\"title\">Specific cautions:</p>\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithIndications\">\n<p outputclass=\"title\">When used for rheumatoid arthritis</p>\n<p>\n<ph outputclass=\"caution\">predisposition to infection</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hepatitis B infection and reactivation</p>\n<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>rituximab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>\n</sectiondiv>\n<sectiondiv>\n<p>For full details on cautions, consult product literature or local treatment protocol.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49884\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/rituximab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (rituximab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49835\" outputclass=\"sideEffects\" rev=\"1.34\" parent=\"/drugs/rituximab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">antibody formation</ph>; <ph outputclass=\"sideEffect\">aplastic anaemia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">lupus erythematosus-like syndrome</ph>; <ph outputclass=\"sideEffect\">migraine</ph>; <ph outputclass=\"sideEffect\">muscle spasm</ph>; <ph outputclass=\"sideEffect\">pancytopenia</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">progressive multifocal leucoencephalopathy</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rhinitis</ph>; <ph outputclass=\"sideEffect\">severe fatal skin reactions</ph>; <ph outputclass=\"sideEffect\">severe skin reactions (permanently discontinue treatment if occurs)</ph>; <ph outputclass=\"sideEffect\">sore throat</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome (permanently discontinue treatment if occurs)</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis (permanently discontinue treatment if occurs)</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>; <ph outputclass=\"sideEffect\">worsening heart failure</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Progressive multifocal leucoencephalopathy</p>\n<p>Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.</p>\n</sectiondiv>\n<sectiondiv>\n<p>For full details, including management of side-effects, consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49975\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/rituximab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception (in both sexes) required during and for 12 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49875\" outputclass=\"pregnancy\" parent=\"/drugs/rituximab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49994\" outputclass=\"breastFeeding\" parent=\"/drugs/rituximab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid breast-feeding during and for 12 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49803\" outputclass=\"monitoringRequirements\" parent=\"/drugs/rituximab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>For full details on monitoring requirements consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50018\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/rituximab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>MabThera</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1-4&#8239;mg/mL and gently invert bag to avoid foaming.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49866\" outputclass=\"patientAndCarerAdvice\" rev=\"1.15\" parent=\"/drugs/rituximab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p outputclass=\"title\">Alert card</p>\n<p>Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49763\" outputclass=\"nationalFunding\" rev=\"1.49\" parent=\"/drugs/rituximab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA65</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for aggressive non-Hodgkin&#8217;s lymphoma (September 2003)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV.</p>\r\n<p>The use of rituximab for localised (stage I) disease should be limited to clinical trials.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA65\">www.nice.org.uk/TA65</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA137</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma (February 2008)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma.</p>\r\n<p>Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma in remission induced with chemotherapy (with or without rituximab).</p>\r\n<p>Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA137\">www.nice.org.uk/TA137</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA174</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA174\">www.nice.org.uk/TA174</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA193</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:</p>\r\n<ul>\r\n<li>is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), <b>or</b>\r\n</li>\r\n<li>has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide.</li>\r\n</ul>\r\n<p>Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA193\">www.nice.org.uk/TA193</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA195</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p>\r\n<p>Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA226</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for the first-line maintenance treatment of follicular non-Hodgkin&#8217;s lymphoma (June 2011)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins&#8217;s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA226\">www.nice.org.uk/TA226</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA243</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with:</p>\r\n<ul>\r\n<li>cyclophosphamide, vincristine and prednisolone (CVP);</li>\r\n<li>cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);</li>\r\n<li>mitoxantrone, chlorambucil and prednisolone (MCP);</li>\r\n<li>cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); <i>or</i>\r\n</li>\r\n<li>chlorambucil</li>\r\n</ul>\r\n<p>is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA243\">www.nice.org.uk/TA243</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA308</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)</p>\r\n<p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:</p>\r\n<ul>\r\n<li>further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, <b>or</b>\r\n</li>\r\n<li>cyclophosphamide is contraindicated or not tolerated, <b>or</b>\r\n</li>\r\n<li>the patient has not completed their family, and treatment with cyclophosphamide may materially affect their fertility, <b>or</b>\r\n</li>\r\n<li>the disease has remained active or progressed despite a course of cyclophosphamide lasting 3&#8211;6 months <b>or</b>\r\n</li>\r\n<li>the patient has had uroepithelial malignancy.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA308\">www.nice.org.uk/TA308</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2013) that Rituximab (<i>MabThera</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland, in combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener&#8217;s) and microscopic polyangiitis. It is restricted to use in patients who have relapsed following treatment with cyclophosphamide or who are intolerant to or unable to receive cyclophosphamide.</p>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (June 2014) that subcutaneous rituximab (<i>MabThera</i>)<tm tmtype=\"reg\"/> is accepted for restricted use within NHS Scotland, in accordance with UK licensing, except in the maintenance setting, where use is restricted to patients who have responded to induction therapy with rituximab plus chemotherapy.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5662-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/rituximab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101337\" title=\"Solution for injection\" namespace=\"/drugs/rituximab/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75274\" title=\"Solution for infusion\" namespace=\"/drugs/rituximab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"2\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"2\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78556\" namespace=\"/treatment-summaries/platelet-disorders\" title=\"Platelet disorders\" count=\"1\" rel=\"backlink\">Platelet disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1300\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/rituximab\" title=\"Rituximab\" count=\"1\" rel=\"link\">Rituximab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" count=\"1\" rel=\"link\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101337\" namespace=\"/drugs/rituximab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75274\" namespace=\"/drugs/rituximab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5662",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/rituximab",
    "basename": "rituximab",
    "title": "RITUXIMAB",
    "interactants": [
        {
            "id": "bnf_int_1300",
            "label": "Rituximab"
        }
    ],
    "vtmid": "108809004",
    "drugClassification": [
        "Monoclonal antibodies (anti-lymphocyte)",
        "Monoclonal antibodies (antineoplastic)"
    ],
    "inheritsFromClass": [
        "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (in combination with methotrexate)",
                        "html": "Treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them (in combination with methotrexate)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1 g, then 1 g after 2 weeks, patients should receive premedication before each infusion (consult product literature for details).",
                        "html": "<p>1&#8239;g, then 1&#8239;g after 2&#8239;weeks, patients should receive premedication before each infusion (consult product literature for details).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of previously untreated stage III&#8211;IV follicular lymphoma (in combination with other chemotherapy)",
                        "html": "Treatment of previously untreated stage III&#8211;IV follicular lymphoma (in combination with other chemotherapy)"
                    },
                    {
                        "textContent": "Maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (in combination with other chemotherapy)",
                        "html": "Maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (in combination with other chemotherapy)"
                    },
                    {
                        "textContent": "Treatment of diffuse large B-cell non-Hodgkin's lymphoma (in combination with other chemotherapy)",
                        "html": "Treatment of diffuse large B-cell non-Hodgkin's lymphoma (in combination with other chemotherapy)"
                    },
                    {
                        "textContent": "Treatment of chemotherapy-resistant or relapsed stage III&#8211;IV follicular non-Hodgkin's lymphoma",
                        "html": "Treatment of chemotherapy-resistant or relapsed stage III&#8211;IV follicular non-Hodgkin's lymphoma"
                    },
                    {
                        "textContent": "Previously untreated or relapsed chronic lymphocytic leukaemia",
                        "html": "Previously untreated or relapsed chronic lymphocytic leukaemia"
                    },
                    {
                        "textContent": "Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis (in combination with glucocorticoids)",
                        "html": "Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis (in combination with glucocorticoids)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Patients should receive premedication before each dose (consult product literature for details) (consult product literature or local protocols).",
                        "html": "<p>Patients should receive premedication before each dose (consult product literature for details) (consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)",
                "html": "Severe heart failure (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)"
            },
            {
                "type": "contraindications",
                "textContent": "severe infection",
                "html": "severe infection"
            },
            {
                "type": "contraindications",
                "textContent": "severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)",
                "html": "severe, uncontrolled heart disease (when used to treat granulomatosis with polyangiitis or microscopic polyangiitis)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For full details on contraindications, consult product literature.",
                "html": "<p>For full details on contraindications, consult product literature.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "History of cardiovascular disease; in adults exacerbation of angina, arrhythmia, and heart failure have been reported",
                "html": "History of cardiovascular disease; in adults exacerbation of angina, arrhythmia, and heart failure have been reported"
            },
            {
                "type": "cautions",
                "textContent": "patients receiving cardiotoxic chemotherapy; in adults exacerbation of angina, arrhythmia, and heart failure have been reported",
                "html": "patients receiving cardiotoxic chemotherapy; in adults exacerbation of angina, arrhythmia, and heart failure have been reported"
            },
            {
                "type": "cautions",
                "textContent": "transient hypotension occurs frequently during infusion (anti-hypertensives may need to be withheld for 12 hours before infusion)",
                "html": "transient hypotension occurs frequently during infusion (anti-hypertensives may need to be withheld for 12 hours before infusion)"
            }
        ],
        "cautionsOrContraindicationsWithIndications": [
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "predisposition to infection",
                "html": "predisposition to infection",
                "specificity": {
                    "textContent": "When used for rheumatoid arthritis",
                    "html": "When used for rheumatoid arthritis",
                    "indications": [
                        "rheumatoid arthritis"
                    ]
                }
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Hepatitis B infection and reactivation",
                "textContent": "Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking rituximab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).",
                "html": "<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>rituximab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>"
            },
            {
                "type": "importantAdvice",
                "textContent": "For full details on cautions, consult product literature or local treatment protocol.",
                "html": "<p>For full details on cautions, consult product literature or local treatment protocol.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (rituximab).",
                "html": "<p>Appendix 1 (rituximab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "antibody formation",
                        "html": "antibody formation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "aplastic anaemia",
                        "html": "aplastic anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lupus erythematosus-like syndrome",
                        "html": "lupus erythematosus-like syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "migraine",
                        "html": "migraine",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "muscle spasm",
                        "html": "muscle spasm",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancytopenia",
                        "html": "pancytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "progressive multifocal leucoencephalopathy",
                        "html": "progressive multifocal leucoencephalopathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rhinitis",
                        "html": "rhinitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe fatal skin reactions",
                        "html": "severe fatal skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "severe skin reactions (permanently discontinue treatment if occurs)",
                        "html": "severe skin reactions (permanently discontinue treatment if occurs)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sore throat",
                        "html": "sore throat",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome (permanently discontinue treatment if occurs)",
                        "html": "Stevens-Johnson syndrome (permanently discontinue treatment if occurs)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis (permanently discontinue treatment if occurs)",
                        "html": "toxic epidermal necrolysis (permanently discontinue treatment if occurs)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "worsening heart failure",
                        "html": "worsening heart failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Progressive multifocal leucoencephalopathy",
                "textContent": "Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.",
                "html": "<p>Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.</p>"
            },
            {
                "type": "advice",
                "textContent": "For full details, including management of side-effects, consult product literature.",
                "html": "<p>For full details, including management of side-effects, consult product literature.</p>"
            },
            {
                "type": "advice",
                "textContent": "Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.",
                "html": "<p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception (in both sexes) required during and for 12 months after treatment.",
                "html": "<p>Effective contraception (in both sexes) required during and for 12 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.",
                "html": "<p>Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid breast-feeding during and for 12 months after treatment.",
                "html": "<p>Avoid breast-feeding during and for 12 months after treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "For full details on monitoring requirements consult product literature.",
                "html": "<p>For full details on monitoring requirements consult product literature.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (MabThera ), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1-4 mg/mL and gently invert bag to avoid foaming.",
                "html": "<p>For <i>intravenous infusion</i> (<i>MabThera</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1-4&#8239;mg/mL and gently invert bag to avoid foaming.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "title": "Alert card",
                "textContent": "Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.",
                "html": "<p>Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA65",
                        "label": "www.nice.org.uk/TA65"
                    }
                ],
                "fundingIdentifier": "NICE TA65",
                "textContent": "Rituximab for aggressive non-Hodgkin&#8217;s lymphoma (September 2003) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV. The use of rituximab for localised (stage I) disease should be limited to clinical trials.\n\nwww.nice.org.uk/TA65",
                "html": "<p outputclass=\"title\">Rituximab for aggressive non-Hodgkin&#8217;s lymphoma (September 2003)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV.</p> <p>The use of rituximab for localised (stage I) disease should be limited to clinical trials.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA65\">www.nice.org.uk/TA65</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA137",
                        "label": "www.nice.org.uk/TA137"
                    }
                ],
                "fundingIdentifier": "NICE TA137",
                "textContent": "Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma (February 2008) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma. Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma in remission induced with chemotherapy (with or without rituximab). Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).\n\nwww.nice.org.uk/TA137",
                "html": "<p outputclass=\"title\">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma (February 2008)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma.</p> <p>Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin&#8217;s lymphoma in remission induced with chemotherapy (with or without rituximab).</p> <p>Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin&#8217;s lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA137\">www.nice.org.uk/TA137</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA174",
                        "label": "www.nice.org.uk/TA174"
                    }
                ],
                "fundingIdentifier": "NICE TA174",
                "textContent": "Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.\n\nwww.nice.org.uk/TA174",
                "html": "<p outputclass=\"title\">Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA174\">www.nice.org.uk/TA174</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA193",
                        "label": "www.nice.org.uk/TA193"
                    }
                ],
                "fundingIdentifier": "NICE TA193",
                "textContent": "Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition: is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), or has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide. Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.\n\nwww.nice.org.uk/TA193",
                "html": "<p outputclass=\"title\">Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:</p> <ul> <li>is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), <b>or</b> </li> <li>has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide.</li> </ul> <p>Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA193\">www.nice.org.uk/TA193</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA195",
                        "label": "www.nice.org.uk/TA195"
                    }
                ],
                "fundingIdentifier": "NICE TA195",
                "textContent": "Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.\n\nwww.nice.org.uk/TA195",
                "html": "<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p> <p>Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA226",
                        "label": "www.nice.org.uk/TA226"
                    }
                ],
                "fundingIdentifier": "NICE TA226",
                "textContent": "Rituximab for the first-line maintenance treatment of follicular non-Hodgkin&#8217;s lymphoma (June 2011) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins&#8217;s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.\n\nwww.nice.org.uk/TA226",
                "html": "<p outputclass=\"title\">Rituximab for the first-line maintenance treatment of follicular non-Hodgkin&#8217;s lymphoma (June 2011)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins&#8217;s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA226\">www.nice.org.uk/TA226</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA243",
                        "label": "www.nice.org.uk/TA243"
                    }
                ],
                "fundingIdentifier": "NICE TA243",
                "textContent": "Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with: cyclophosphamide, vincristine and prednisolone (CVP); cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); mitoxantrone, chlorambucil and prednisolone (MCP); cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); or chlorambucil is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.\n\nwww.nice.org.uk/TA243",
                "html": "<p outputclass=\"title\">Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with:</p> <ul> <li>cyclophosphamide, vincristine and prednisolone (CVP);</li> <li>cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);</li> <li>mitoxantrone, chlorambucil and prednisolone (MCP);</li> <li>cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); <i>or</i> </li> <li>chlorambucil</li> </ul> <p>is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA243\">www.nice.org.uk/TA243</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA308",
                        "label": "www.nice.org.uk/TA308"
                    }
                ],
                "fundingIdentifier": "NICE TA308",
                "textContent": "Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014) This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if: further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, or cyclophosphamide is contraindicated or not tolerated, or the patient has not completed their family, and treatment with cyclophosphamide may materially affect their fertility, or the disease has remained active or progressed despite a course of cyclophosphamide lasting 3&#8211;6 months or the patient has had uroepithelial malignancy.\n\nwww.nice.org.uk/TA308",
                "html": "<p outputclass=\"title\">Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)</p> <p>This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:</p> <ul> <li>further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, <b>or</b> </li> <li>cyclophosphamide is contraindicated or not tolerated, <b>or</b> </li> <li>the patient has not completed their family, and treatment with cyclophosphamide may materially affect their fertility, <b>or</b> </li> <li>the disease has remained active or progressed despite a course of cyclophosphamide lasting 3&#8211;6 months <b>or</b> </li> <li>the patient has had uroepithelial malignancy.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA308\">www.nice.org.uk/TA308</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101337",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75274",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78556",
                "label": "Platelet disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1300",
                "label": "Rituximab",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34582",
                "label": "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101337",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75274",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}